Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. (LXRP)

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans Additional Clinical Trials Following Successful Tests

Posted on February 25, 2019 by MissionIR

Company recently announced significant findings of cardiovascular performance improvements with TurboCBD Lexaria plans additional human clinical trials of CBD Company is now moving forward with clinical studies on oral forms of nicotine delivery following a large investment agreement Lexaria Bioscience … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases Additional Significant Findings of its DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Posted on February 21, 2019 by MissionIR

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company’s proprietary, DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon completion of further data analyses from its 2018 randomized, … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries

Posted on February 15, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding success through its ability to form subsidiaries specializing in the use of its patented drug-delivery platform, DehydraTECH. A recent article discussing the company reads, “DehydraTECH is a drug-delivery platform patented for cannabidiol … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH

Posted on February 13, 2019 by MissionIR

LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange for equity and licensing rights … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry

Posted on February 11, 2019 by MissionIR

Big corporations are investing in the cannabis industry Major tobacco company provides financing for LXRP LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors Lexaria is a unique company doing business on its own terms The … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology

Posted on February 7, 2019 by MissionIR

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, recently struck a deal with a large tobacco partner, securing significant R&D financing for the company’s DehydraTECH absorption platform (http://ibn.fm/Kx7Cm). A recent article discussing the company reads, “Through … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Seeks to Improve Lives through Revolutionary Nicotine Delivery Method

Posted on January 31, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined forces with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s patented DehydraTECHÔ technology to potentially … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Receives New R&D Funding for Oral Nicotine Delivery Technology

Posted on January 31, 2019 by MissionIR

LXRP subsidiary Lexaria Nicotine LLC enters definitive investment agreement with large tobacco company to receive R&D funding in exchange for licensing and equity Partner has provided initial $1 million – with an option for up to $11 million more – … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery

Posted on January 25, 2019 by MissionIR

Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Acquires a $12 Million Investor

Posted on January 24, 2019 by MissionIR

Lexaria Nicotine LLC partners with one of the world’s largest tobacco companies Opportunity to change nicotine delivery and improve the lives of millions Retains ownership of DehydraTECH while licensing the technology out to multiple industries Lexaria Bioscience Corp. (CSE: LXX) … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment